COVID-19期间HIV与丙型肝炎抗病毒药物的配药情况:美国全国数据的间断时间序列分析
本研究采用间断时间序列分析,基于IQVIA全国处方审计数据(覆盖92%美国零售药房及70%邮购和长期护理药房),评估美国COVID-19初始暴发对HIV和HCV抗病毒药物月度配药量的即时及1年影响。结果显示,直接抗病毒药物(DAA)配药量在暴发后下降近三分之一,至2021年4月仍未恢复至疫情前水平,而抗逆转录病毒治疗(ART)和暴露前预防(PrEP)配药变化很小。
要点
- COVID-19暴发后DAA处方配药量下降近三分之一。
- 至2021年4月,DAA月度配药量仍未恢复至疫情前水平。
- ART和PrEP配药量在同一时期变化很小。
核心结论
- 美国用于治疗HCV的DAA配药量在COVID-19暴发初期下降,且尚未完全恢复至疫情前水平。
- 解决照护障碍对于实现国家HIV和丙型肝炎消除目标至关重要。
研究设计与样本
- 研究采用间断时间序列分析,使用IQVIA全国处方审计数据(包括92%的美国零售药房和70%的美国邮购及长期护理药房)。
- 分析比较了美国COVID-19初始暴发前2年与后1年的月度配药处方变化,并排除2020年4月作为洗脱期。
- 采用拟合线性分段回归模型评估即时水平和斜率变化,并按新发/续药、年龄组、支付方类型和配送渠道进行分层分析。
主要发现
- COVID-19初始暴发后,DAA处方配药量下降近三分之一。
- COVID-19暴发与DAA总处方量的即时水平下降相关,随后月度配药斜率上升。
- 至2021年4月,DAA月度配药量仍未恢复至疫情前水平。
- 在同一时期,ART和PrEP配药量变化很小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Little is known about the potential changes in the dispensation of life-saving hepatitis C virus (HCV) and HIV antivirals after the initial U.S. outbreak of COVID-19. The objective of this study was to describe the immediate and 1-year impacts of the U.S. outbreak of COVID-19 on monthly dispensing of HIV and HCV antivirals, specifically direct-acting antivirals (DAA) to treat HCV, antiretroviral therapy (ART) to treat HIV, and pre-exposure prophylaxis (PrEP) to prevent HIV. METHODS: Authors used interrupted time-series analysis, examining IQVIA National Prescription Audit (includes 92% of U.S. retail pharmacies and 70% of U.S. mail order and long-term care pharmacies) for changes in monthly dispensed prescriptions, 2 years before and 1 year after the initial U.S. COVID-19 outbreak. Fitted linear segmented regression models were used to assess immediate level and slope changes, excluding data from April 2020 as a washout period. Authors stratified analyses by new/refill, age group, payer type, and delivery channel. RESULTS: After the initial outbreak, DAA prescription dispensing declined by almost one third. The COVID-19 outbreak was associated with an immediate-level decrease in total DAA prescriptions, followed by a slope increase in monthly dispensing. However, by April 2021, monthly DAA dispensing had not recovered to prepandemic levels. In contrast, ART and PrEP dispensing changed little over the same time period. CONCLUSIONS: U.S. dispensing of DAAs to treat HCV fell at the start of the U.S. COVID-19 outbreak and has yet to fully recover to prepandemic levels. Addressing barriers to care is crucial to reaching national HIV and hepatitis C elimination goals.
引用
- Levengood TW, Aronsohn AI, Chua KP, et al. Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data. Am J Prev Med. 2022. PMID: 35738958. doi:10.1016/j.amepre.2022.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。